Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALLAD BELGIUM: Adjuvant chemotherapy for small bowel adenocarcinoma
2018-002831-65Phase 3Active
- Sponsor
- Belgian Group of Digestive Oncology
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fluorouracil, folinic acid, capecitabine and oxaliplatin in small bowel adenocarcinoma (SBA) (2 arms), sponsored by Belgian Group of Digestive Oncology. Primary endpoint: Disease-free survival. Started Oct 2018; status: active.
02
Drugs
fluorouracilfolinic acidcapecitabineoxaliplatin
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on 2018-002831-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002831-65.